长江生命科技(00775.HK)股价飙八成 美国附属黑色素瘤抗原疫苗免疫疗法研究初始数据正面
长江生命科技(00775.HK)中午公布,旗下美国一间专注於肿瘤免疫学的生物制药公司Polynoma的黑色素瘤抗原疫苗免疫疗法研究初始数据正面,刺激股价午後飙八成,现造0.64元,创逾年新高,成交放量大增至5,487万股。
长江生命科技表示,Polynoma将於今年11月8日在美国马里兰州国家港口举行的癌症免疫疗法学会2019年度年会上,展示其从黑色素瘤抗原疫苗免疫疗法研究(其现正进行的研究性黑色素瘤候选疫苗seviprotimut-L第三阶段临床研究)所得的临床数据。 公司认为,黑色素瘤抗原疫苗免疫疗法研究的初始数据令人鼓舞,而且从分析中所得的功效和安全性的确切证据可见,seviprotimut-L有潜力作为局限性黑色素瘤患者辅助性疗法的重要新选项。从黑色素瘤抗原疫苗免疫疗法研究中获得的初步数据亦显示,seviprotimut-L可能是黑色素瘤疫苗疗法的一项重要革新,迄今为止尚未有任何疫苗获批准用於黑色素瘤辅助性疗法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.